SCL Science

SCL Science Net Debt

The Net Debt of SCL Science (246960.KQ) as of Oct 16, 2026 is 12.16 B KRW. In the previous year, Net Debt was 2.55 B KRW — a change of 376.57% (higher).

Net Debt

12.16 BKRW

YoY

376.57%

Last updated:

Net Debt of SCL Science is 2025 12.16 B KRW. Net Debt of SCL Science was 2024 2.55 B KRW. It decreases by 376.57% higher compared to the previous year.

The SCL Science Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-6.58 B KRW
Jan 1, 2019
-10.30 B KRW
Jan 1, 2020
-2.01 B KRW
Jan 1, 2021
6.75 B KRW
Jan 1, 2022
5.54 B KRW
Jan 1, 2023
-2.23 B KRW
Jan 1, 2024
2.55 B KRW
Jan 1, 2025
12.16 B KRW
The SCL Science Net Debt history
YEARNet DebtYoY
12.16 BKRW+376.57%
2.55 BKRW-214.38%
-2.23 BKRW-140.26%
5.54 BKRW-17.91%
6.75 BKRW-436.05%
-2.01 BKRW-80.49%
-10.30 BKRW+56.55%
-6.58 BKRW-4,511.79%
149.10 MKRW-106.46%
-2.31 BKRW-124.74%
9.32 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Net Debt of SCL Science is 12.16 B KRW in 2025.

Net Debt of SCL Science changed from 2.55 B KRW to 12.16 B KRW, representing a 376.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt SCL Science since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SCL Science

All Key Metrics — SCL Science